# Treatments for mitochondrial diseases
Mitochondrial diseases are complex and have no single unified treatment. The approach focuses on alleviating symptoms, supporting the energy supply of body cells, and preventing further damage. Because mitochondrial diseases can present very differently, treatments are highly tailored to the type of disease, the organs involved, and the severity of symptoms.
Supportive nutrition and metabolic management
Many people with mitochondrial diseases benefit from adjustments in nutrition and energy management. This can mean, for example, more small, regular meals instead of heavy meals, or food choices that are well absorbed. Some specialists also recommend nutritional supplements such as L-arginine or certain fatty acids, although the evidence for this is mixed.
ResearchediPositive results in clinical studies, not yet standard treatment
L-arginine and other amino acid intermediates are being investigated for their role in improving energy metabolism and organ perfusion. Research shows that certain amino acids can help support mitochondrial function, but this approach has not yet become part of standard guidelines as a regular treatment.
ResearchediPositive results in clinical studies, not yet standard treatment
Coenzyme Q10 (ubiquinone) has been studied for a long time for mitochondrial diseases. This substance works as an electron carrier in mitochondrial energy production. In some randomized studies, a cautiously positive effect has been reported, especially in certain genetic forms, but consensus on dosing and indication is still lacking.
Adequate calorie and fluid status are crucial. Dehydration and malnutrition can trigger attacks of severe deterioration, especially in certain forms of mitochondrial encephalopathies.
Treatment of epilepsy
Seizures occur frequently in mitochondrial diseases, especially in hereditary neurometabolic forms. The approach does not differ fundamentally from epilepsy treatment elsewhere, but doctors are cautious with certain anticonvulsants because they can worsen mitochondrial function.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Standard anticonvulsants such as valproic acid are approved for epilepsy control, but in mitochondrial diseases this is advised against, because valproic acid can disrupt mitochondrial energy production. This is why doctors are more cautious in their choice of medication than with common epilepsy.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Levetiracetam, lamotrigine, and other modern anticonvulsants are generally better tolerated and are preferred. This approach is mentioned in the clinical guidelines of mitochondrial disease centers.
Cardiac Protection
Some mitochondrial diseases affect the heart (cardiomyopathies), where the heart can pump less and less effectively. Treatment focuses on supporting heart function and preventing further damage.
ProveniIncluded in official guidelines, or approved by EMA or FDA
ACE inhibitors and beta-blockers are standard approaches for heart failure and are also used in mitochondrial cardiomyopathies. These medications work by reducing the strain on the heart and suppressing harmful hormonal responses. Side effects are known from heart failure treatment (low blood pressure, fatigue).
ResearchediPositive results in clinical studies, not yet standard treatment
Tafamidis has been investigated for protecting cardiac mitochondria in certain protein misfolding diseases that also affect mitochondria. This substance stabilizes certain proteins and can prevent further cardiac damage in specific forms, but is not routinely applied.
Neurological symptom management
Many people suffer from progressive muscle weakness, spasticity, and neurological symptoms such as ataxia (coordination disorder) and tremor.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Physiotherapy and movement exercises to maintain and where possible strengthen muscle function and motor capacity. This is recognized as an essential part of management and has no medication side effects, but requires more careful dosing because overexertion can lead to deterioration.
ResearchediPositive results in clinical studies, not yet standard treatment
Baclofen is being investigated for spasticity (increased muscle tone). This medication works by calming the nervous system, but it is insufficiently studied whether it is beneficial in this population without side effects.
Protection against oxidative damage
Mitochondrial dysfunction leads to accumulation of harmful free radicals. Antioxidants are therefore being investigated, although a strongly proven mechanism of action is still lacking.
ResearchediPositive results in clinical studies, not yet standard treatment
Antioxidants such as vitamin E, vitamin C and alpha-lipoic acid are given in some centers to counteract oxidative stress. Laboratory studies and animal models show that these substances can neutralize harmful radicals, but large randomized studies in humans are still lacking.
ExperimentaliOngoing in study setting, outcome still unknown
Urolithin A, a derivative of certain plant-based foods, is under investigation for its possible role in clearing damaged mitochondria (a process called mitophagy). Animal studies suggest a neuroprotective effect, but human studies are still limited.
ExperimentaliOngoing in study setting, outcome still unknown
Cannabidiol is undergoing preclinical research for protection against neuronal damage. Cell studies show that it can prevent certain harmful protein accumulation and maintain mitochondrial integrity, but human data are still very preliminary.
Liver and kidney protection
Mitochondrial diseases can affect the liver and kidneys, which requires additional care.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular monitoring and prevention of further harmful factors (such as certain medications and infections) is standard. Avoidance of certain risk factors is mentioned in guidelines.
ResearchediPositive results in clinical studies, not yet standard treatment
Specific protective substances for the liver or kidney are still largely in the research phase. Studies into improvements in liver and kidney function through manipulation of mitochondrial processes are ongoing, but practical application is still limited.
Infection control and prevention
Infections are an important risk because they greatly increase the energy demands of cells.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Careful infection prevention and early treatment of infections are part of the standard approach. Vaccinations (to the extent tolerated) are recommended. This is not a medication but part of good management.
Genetic and experimental therapies
For certain inherited forms of mitochondrial diseases, new treatments are being investigated.
ExperimentaliOngoing in study setting, outcome still unknown
Gene therapy and therapies targeting mutant mitochondrial DNA are in research and clinical trial phases. For certain inherited forms (for example, Leber hereditary optic neuropathy), small steps have been taken, but many forms are not yet treatable with this approach.
ExperimentaliOngoing in study setting, outcome still unknown
Mitochondrial transplantation and cybernetic interventions to replace dysfunctional mitochondria are highly experimental and available only within research frameworks.
Psychosocial and palliative care
For many people with severe forms, attention to quality of life, pain management and mental health is crucial.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Psychological support, occupational and physiotherapy aimed at adaptations in daily life, and where necessary palliative care are part of the multidisciplinary package. This is recognized in international guidelines.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._